Hidden in the heart of Mt. Gilead, Ohio sits a pink-hued bakery that’s turning carbohydrates into religious experiences and making locals willingly set their alarms for dawn just to beat the morning ...

Presented in the form of first-person witness testimonies, they map the parallel lives of two young women: one, Daisy, raised in Canada, the other, Agnes Jemima, in Gilead. Over the course ... seem ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

"Stigma isn't just a social issue; it's a public health crisis." says Marcus Wilson, Gilead Senior Director, U.S. Public Affairs, HIV Advocacy. "It determines the quality of care that people ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Gilead Sciences (GILD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...

GILD opened at $116.04 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $62.07 and a 52-week ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Advertisement Moss portrays June, or Offred, as she is called once she is forced to be a surrogate for a wealthy family under the totalitarian government known as Gilead. "We've been afraid of ...

At a news briefing in Geneva, UNAIDS Executive Director Winnie Byanyima said the deal would involve Trump enabling the U.S. company Gilead to produce and license its “magical” prevention drug ...